| HRA005077
(Open Access)
|
Metabolic reprogramming is a hallmark and therapeutic target in cancer, as cancer cells accumulate metabolic changes to meet biosynthetic and energy demands, sustaining rapid proliferation while generating metabolic heterogeneity. Heterogeneous metabolic preferences and dependencies exist among different cancer types and even within cancer cells of the same tissue. Cancer cells acquire metabolic adaptability by responding to various endogenous and exogenous signals, some of which promote malignant cell growth and render them vulnerable to inhibition by key pathway inhibitors. To explore the metabolic features of acute B-cell lymphoblastic leukemia (B-ALL), we collected bone marrow samples from newly diagnosed patients in the PDT-ALL-2016 cohort at Southern Hospital from 2016-2020 for transcriptome sequencing (n=91) and untargeted metabolomics profiling (n=69), in addition to conducting transcriptome sequencing on two B-ALL cell lines (BALL-1 and HAL-01). |
